Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.53 |
| ▸ | HTR3B | O95264 | 1/20 | 0.53 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595694 | 0.84 | ALDH1A1 (0.68) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL3953114 | 0.82 | MAPT (0.59) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL15689068 | 0.81 | HDAC6 (0.50) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL3951468 | 0.81 | ABCB1 (0.54) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL13348855 | 0.79 | MAPT (0.60) | HDAC6MAPTKMT2AMEN1MAPK1 | |
| SCHEMBL8024017 | 0.78 | DGAT1 (0.61) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL10535215 | 0.77 | ALDH1A1 (0.62) | ROCK1HDAC6MAPTGAAALDH1A1 | |
| SCHEMBL3951214 | 0.76 | AHR (0.55) | HTR3EHTR3BHTR3AROCK1HTR3D | |
| SCHEMBL7823 | 0.75 | — | — | |
| SCHEMBL10983245 | 0.75 | GAA (0.47) | MAPTGAAALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481538-B2 | Heterocyclic inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2066676-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2008036272-A1 | HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144739-A1 | HETEROCYCLIC INHIBITORS OF C-MET AND USES THEREOF | MET, RET, ABL1 | HTR3E 1091/4885HTR3B 1159/4885HTR3A 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.